Global Kras Inhibitors Market GRÖSSEN- UND MARKTANTEILSANALYSE - WACHSTUMSTRENDS UND PROGNOSEN (2024 - 2031)
Global Kras Inhibitors Market wird segmentiert Durch Drogentyp (kleine Molekülinhibitoren, monoklonale Antikörper, Kombinationstherapien), Durch Indication (Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Cancer), By Route of Administration (Oral, Intravenous, Others), By Cancer Type (Lung Cancer, Pancreatic Cancer, Colorectal Cancers, Andere) Der Bericht bietet den Wert (in Mio. USD) für die genannten Segmente.
Competitive overview of Global Kras Inhibitors Market
Zu den wichtigsten Akteuren des globalen Kras Inhibitors Markt gehören Amgen, Boehringer Ingelheim, Mirati Therapeutics, Novartis, BridgeBio Pharma, Erasca, Innovent Biologics, Inc., Incyte, Jemincare und Cardiff Oncology, Inc.
Global Kras Inhibitors Market Leaders
- Amgen
- Boehringer Ingelheim
- Mirati Therapeuten
- Novartis
- BrückeBio Pharma
*Disclaimer: Major players are listed in no particular order.
Global Kras Inhibitors Market - Competitive Rivalry, 2023
Global Kras Inhibitors Market
Market Consolidated
(Dominated by major players)
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
(Highly competitive with lots of players.)
*Source: Coherent Market Insights